Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by US Food and Drug Administration

Takeda announced that the FDA has accepted and granted priority review of the Biologics License Application for TAK-003, the company’s investigational dengue vaccine candidate. In the US, TAK-003 is being evaluated for the prevention of dengue disease caused by any dengue virus serotype in individuals 4 years through 60 years of age.